The World Health Organization (WHO) has confirmed Uganda’s first case of Marburg virus disease in 2026, complicating an already challenging public health landscape as the country continues to manage an Ebola outbreak. The case—an 18-month-old girl from Kyegegwa district in western Uganda—was initially suspected to be Ebola but tested positive for Marburg after laboratory confirmation, according to Catherine Smallwood, incident manager for the Ebola desk at WHO’s East Africa regional office in Kampala.
Key takeaways
- Uganda’s first confirmed Marburg case in 2026 involves an 18-month-old girl from Kyegegwa district who died after initial suspected Ebola diagnosis
- The case was identified through Uganda’s systematic testing protocol for all suspected viral haemorrhagic fever cases, demonstrating laboratory surveillance capacity
- WHO is already deploying response teams across Uganda to support disease containment while the country simultaneously manages an ongoing Ebola outbreak
Viral Haemorrhagic Fever Threats in East Africa
Uganda managing dual outbreak response, 2026
Source: WHO Kampala office, June 2026 | Georgian Medical Journal News
Confirmation Through Routine Surveillance
According to Catherine Smallwood, the case was detected through Uganda’s rigorous testing protocol for viral haemorrhagic fever suspects. “WHO did receive official communication from Uganda on 30 June of one confirmed case of Marburg disease,” Smallwood told The BMJ. The child had initially presented as a suspected Ebola case but laboratory testing revealed Marburg virus instead, illustrating the importance of differential diagnosis in outbreak response.
This detection mechanism reflects established practice at Uganda’s national laboratories, which screen all suspected haemorrhagic fever cases against multiple viral pathogens. The identification of Marburg rather than Ebola underscores that clinical presentation alone is insufficient for accurate diagnosis—a principle emphasized in CDC guidance on viral haemorrhagic fever diagnosis.
WHO’s Expanded Response Amid Dual Outbreak Challenge
The WHO has confirmed it is already supporting Uganda’s containment efforts across multiple sites. Smallwood indicated that WHO teams are “supporting a range of responses across the country” to manage both the Marburg case and the concurrent Ebola outbreak. Uganda’s health ministry declined to provide additional comment to The BMJ at the time of reporting.
The emergence of Marburg during an active Ebola response presents logistical and epidemiological complexity. Both diseases cause viral haemorrhagic fever with similar clinical features, but require distinct case management protocols and contact tracing strategies. WHO’s presence in-country positions the organization to coordinate laboratory confirmation, case isolation, and contact follow-up for both pathogens simultaneously.
WHO confirmed Uganda’s first Marburg case on 30 June 2026—an 18-month-old girl from Kyegegwa who initially presented as a suspected Ebola case but tested positive for Marburg virus through routine viral haemorrhagic fever screening.
— Catherine Smallwood, Incident Manager, WHO Ebola Desk, Kampala (The BMJ, 2026)
Implications for Regional Outbreak Management
The detection of Marburg in Uganda raises questions about the geographic distribution of viral haemorrhagic fevers in East Africa. While Ebola remains the acute crisis, this case highlights that multiple haemorrhagic pathogens may be circulating simultaneously or in proximity—a scenario that demands strengthened surveillance and laboratory capacity throughout the region.
This incident demonstrates the value of Uganda’s commitment to comprehensive viral screening. However, it also signals the need for sustained international support to maintain diagnostic capacity and response readiness across global health threats. The WHO continues to coordinate technical guidance for countries managing multiple concurrent outbreaks.
What this means
Frequently asked questions
How are Marburg and Ebola virus distinguished in the laboratory?
Both viruses cause viral haemorrhagic fever with overlapping clinical symptoms. Laboratory confirmation uses nucleic acid amplification tests (RT-PCR), antigen detection assays, or electron microscopy to identify the specific virus, according to CDC diagnostic protocols. Uganda’s testing confirmed this case as Marburg through such differential testing, despite initial clinical suspicion of Ebola.
What is the case fatality rate of Marburg virus disease?
Marburg case fatality rates vary by outbreak and virus strain, ranging from approximately 24% to 88% in documented cases, according to WHO fact sheets. Early supportive care, including fluid replacement and maintenance of blood pressure and oxygen status, is critical to improving survival outcomes.
How does WHO support countries managing multiple concurrent viral haemorrhagic fever outbreaks?
WHO provides on-the-ground technical teams for case management, contact tracing, laboratory strengthening, and infection prevention and control. The organization also facilitates data sharing between national disease control programs to prevent cross-contamination of surveillance efforts and ensure coordinated resource allocation, as demonstrated in Uganda’s current dual response.
As Uganda deepens its outbreak response, the identification of Marburg alongside Ebola underscores the fragility of disease control in regions where multiple pathogens circulate. Sustained international partnership, robust laboratory networks, and real-time epidemiological surveillance remain essential to containing both threats. Health policy coordination at national and international levels will be critical in the coming weeks.
Source: Uganda confirms Marburg case as Ebola outbreak continues — The BMJ, June 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
